Development of a Prognostic Scoring System for Hepatocellular Carcinoma Patients With Main Portal Vein Tumor Thrombus Undergoing Conventional Transarterial Chemoembolization: An Analysis of 173 Patients
Authors:
Open Access
- 26 August 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Abstract
Background: Patients with hepatocellular carcinoma (HCC) with main portal vein tumor thrombus (mPVTT) have poor prognosis. Promising systemic therapies, such as target therapies, have limited benefits. The purpose of this study is to retrospectively evaluate the benefits of conventional TACE (c-TACE) and to establish a prognostic stratification of HCC patients with mPVTT. Methods: This is a single center retrospective study conducted over 5 years (duration of performing c-TACE), on consecutive HCC patients with mPVTT receiving c-TACE. Univariable and multivariable analysis were used to explore factors independently associated with overall survival (OS). Based on Cox-regression analysis, prognostic models were developed and internally validated by bootstrap methods. Discrimination and performance were measured by Akaike information criterion, concordance index, and likelihood ratio test. Results: A total of 173 patients were included. Median OS was 6.0 months (95%CI: 3.92~8.08). The independent variables correlated with survival were largest tumor diameter, tumor number, mPVTT extension, and AFP. In the final model, patients were assigned 2 points if largest tumor diameter ≥8 cm, or tumor number ≥2, 1point if main trunk was complete obstructed, or AFP ≥400 ng/ml. By summing up these points, patients were divided into three risk groups according to the score at the 15rd and 85th percentiles, in which median OS were 18, 7, and 3.5months, respectively (pConclusions: c-TACE could provide survival benefits in HCC patients with mPVTT and the proposed prognostic stratification may help to identify good candidates for the treatment, and those for whom c-TACE may be futile.Keywords
This publication has 25 references indexed in Scilit:
- Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic areaLiver International, 2016
- Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial‐embolization prognostic scoreLiver International, 2015
- Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinomaWorld Journal of Gastroenterology, 2015
- Practical Effect of Sorafenib Monotherapy on Advanced Hepatocellular Carcinoma and Portal Vein Tumor ThrombosisGut and Liver, 2013
- A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancerAnnals of Oncology, 2013
- Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysisBMC Gastroenterology, 2013
- Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus SorafenibRadiology, 2012
- A new classification for hepatocellular carcinoma with portal vein tumor thrombusJournal of Hepato-Biliary-Pancreatic Sciences, 2010
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2009
- Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patientsGut, 2005